Kiniksa Pharmaceuticals (KNSA) Stock Price, Quote, News & History | Benzinga

Kiniksa Pharmaceuticals International PLC (KNSA) Stock Price, Quote, News & History

KNSANASDAQ

Trade with Public

Trade with Public

$79.03

0.560.71%

At close: Aug 20, 5:00 PM EST

$81.00

2.533.22%

Pre-Market: 7:00 AM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

-

Close

$79.03

Volume / Avg.

505.00 / 749.47K

Day Range

- - -

52 Wk Range

32.89 - 82.94

Market Cap

$6.32B

P/E Ratio

79.78

Dividend Yield

-

Exchange

NASDAQ

RSI

66

Short Interest

10.8%

Days to Cover

4.99

Recent Kiniksa Pharmaceuticals International, PLC News

Crude Oil Down Over 5%; Boeing Shares Rise After Q2 Results

US stocks trade higher, Dow up 1% on Tuesday. Boeing gains 5% after reporting Q2 results. Kiniksa Pharma, OPKO Health, Itron, up over 20%.

Avi Kapoor

Sherwin-Williams Posts Upbeat Q2 Earnings, Joins Itron, Armstrong World And Other Big Stocks Moving Higher On Tuesday

U.S. stocks mixed, Dow Jones up 300 points. Shares of Sherwin-Williams rose 7.8% after reporting better-than-expected earnings and raising FY26 guidance.

Avi Kapoor

CommVault, Kforce, AxoGen And Other Big Stocks Moving Higher On Tuesday

U.S. stocks mixed, Nasdaq down 200 points. CommVault shares up 9.9% after beating earnings estimates. Other gainers include Kforce, Omnicell, and AxoGen.

Avi Kapoor

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Month

Oversold stocks in health care sector present buying opportunity. RSI compares stock's strength on up/down days & predicts short-term performance. Top oversold stocks: KNSA (28) NNOX (28.2) RNA (28.4).

Avi Kapoor

Why CommScope Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

184.97M

Investing Cash Flow (TTM)

-239.07M

Financing Cash Flow (TTM)

37.74M

Free Cash Flow (TTM)

182.84M

Capital Expenditure (TTM)

-2.13M

Net Change in Cash (TTM)

-16.36M

Analyst Trends and Forecast

2

Feb

6

Apr

1

Jun

7

Jul

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.3

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$5.65B

PE Ratio (TTM)

79.78

PE Ratio (FWD)

74.07

PEG Ratio (TTM)

-

PS Ratio (TTM)

7.70

PB Ratio (TTM)

9.42

Earnings Yield % (TTM)

1.25%

Earnings Yield % (FWD)

1.35%

EV / EBITDA (TTM)

55.32

Price / EBITDA (TTM)

63.42

Price / Free Cash Flow (TTM)

35.39

Book Value / Share

$8.38

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$175.68M

Debt to Equity

0.01

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

-

Close

$79.03

Volume / Avg.

505.00 / 749.47K

Day Range

- - -

52 Wk Range

32.89 - 82.94

Market Cap

$6.32B

P/E Ratio

79.78

Dividend Yield

-

Exchange

NASDAQ

RSI

66

Short Interest

10.8%

Days to Cover

4.99

About

Sector

Health Care

Industry

Biotechnology

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The com...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Kiniksa Pharmaceuticals (KNSA) stock?

A

You can purchase shares of Kiniksa Pharmaceuticals (NASDAQ:KNSA) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Kiniksa Pharmaceuticals (KNSA) competitors?

A

Other companies in Kiniksa Pharmaceuticals’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Kiniksa Pharmaceuticals (KNSA) stock?

A

Kiniksa Pharmaceuticals has a consensus price target of $81.56.

Q

What is the current price for Kiniksa Pharmaceuticals (KNSA)?

A

The stock price for Kiniksa Pharmaceuticals (NASDAQ: KNSA) is $81 last updated August 24, 2026 at 7:00 AM EDT.

Q

Does Kiniksa Pharmaceuticals (KNSA) pay a dividend?

A

There are no upcoming dividends for Kiniksa Pharmaceuticals.

Q

When is Kiniksa Pharmaceuticals (NASDAQ:KNSA) reporting earnings?

A

Kiniksa Pharmaceuticals does not have any upcoming earnings scheduled.

Q

Is Kiniksa Pharmaceuticals (KNSA) going to split?

A

There is no upcoming split for Kiniksa Pharmaceuticals.

Q

What sector and industry does Kiniksa Pharmaceuticals (KNSA) operate in?

A

Kiniksa Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.